Renaissance Technologies Adds $5M in Alignment Healthcare, Inc. ($ALHC)

Renaissance Technologies has increased its stake in Alignment Healthcare, Inc. (NasdaqGS: ALHC), according to its latest Form 13F filing with the SEC. The investment firm added 235,900 shares during the reporting period, bringing its total holdings to 2,903,100 shares. The value of this position is approximately $59.6 million.

What Changed in Renaissance Technologies' Alignment Healthcare Position

Renaissance Technologies boosted its holdings in Alignment Healthcare by 235,900 shares, an increase of about 8.84% from its previous stake. Prior to this change, the firm held 2,667,200 shares. This adjustment reflects a growing confidence in the company's prospects, with the total value of the holdings now standing at $59.6 million.

Other Institutional Activity in Alignment Healthcare

Several other major institutional investors also adjusted their positions in Alignment Healthcare. Wellington Management Group LLP increased its stake by 3,028,043 shares, resulting in a total of 17,098,936 shares valued at approximately $301.3 million. FMR LLC added 1,236,129 shares, bringing its total to 15,892,064 shares worth about $280 million. BlackRock, Inc. grew its holdings by 363,883 shares, ending with 14,075,197 shares valued at $248 million. T. Rowe Price Investment Management, Inc. also increased its position by 503,872 shares, totaling 13,147,656 shares valued at $231.7 million.

Alignment Healthcare Stock Snapshot

Shares of Alignment Healthcare (NasdaqGS: ALHC) recently traded around $20.53. The company, with a market cap of approximately $4.43 billion, has a forward P/E ratio of 29.6 and a beta of 1.149. Over the past year, the stock has seen a low of $11.63 and a high of $23.87. The 50-day moving average is $18.67, and the 200-day moving average is $18.68. The company maintains a current ratio of 1.58, a quick ratio of 1.385, and a debt-to-equity ratio of 159.49.

Recent Earnings

Alignment Healthcare reported revenue of about $4.26 billion, with a revenue growth rate of 33.3%. The company's net margin is 0.47%, and it has a return on equity of 12.53%. The next earnings release is scheduled for July 30, 2026.

Insider Buying and Selling at Alignment Healthcare, Inc.

Recent insider transactions at Alignment Healthcare include planned sales by President Dawn Christine Maroney, who sold 30,000 shares on June 15, 2026, and Chief Medical Officer Hyong Kim, who sold 35,951 shares on June 12, 2026. CEO John Kao sold 298,000 shares on June 10, 2026. EVP Joseph Konowiecki sold 25,000 shares on June 11, 2026, but also purchased 122,807 shares on June 3, 2026, in an unplanned transaction.

Analysts Set New Price Targets

Several analysts have maintained their ratings on Alignment Healthcare. On May 26, 2026, Barclays maintained a 'hold' rating with a price target of $16. UBS also maintained a 'hold' rating with a target of $22 on May 1, 2026. JP Morgan had earlier maintained a 'buy' rating with a target of $26 on February 5, 2026. The consensus from 13 analysts is a 'strong buy', with a mean target price of $24.92.

About Alignment Healthcare

Alignment Healthcare, Inc. operates a healthcare platform focused on seniors in the United States, offering Medicare Advantage plans tailored to meet the needs of its customers. Headquartered in Orange, California, and led by CEO John E. Kao, the company was founded in 2013 and employs around 1,849 people. It is part of the healthcare sector, specifically within the healthcare plans industry.

Bottom Line

Renaissance Technologies' increased stake in Alignment Healthcare suggests confidence in the company's future performance. Investors often track such filings to gauge institutional sentiment, though it's important to remember that 13F filings are backward-looking and may not reflect current positions. Alignment Healthcare's stock performance and analyst ratings indicate a positive outlook, supported by a strong market position and growth potential.